These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27346976)

  • 21. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies.
    Sahud M; Zhukov O; Mo K; Popov J; Dlott J
    Haemophilia; 2012 Sep; 18(5):777-81. PubMed ID: 22458845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Remission of a non-haemophilic patient with acquired factor VIII inhibitor treated with infusion of factor VIII and corticosteroid].
    Honda J; Egami K; Osabe S; Natori H; Nakamura E; Tanaka K; Naitou K; Kaji M
    Rinsho Ketsueki; 1989 Apr; 30(4):520-4. PubMed ID: 2504978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B.
    Sahud M; Zhukov O; Naides SJ; Serrano C; Wong E; Dlott J; Racke F
    Haemophilia; 2020 Jul; 26(4):735-740. PubMed ID: 32420682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature.
    Rochanda L; Del Zoppo GJ; Feinstein DI; Liebman HA
    Haemophilia; 2012 Jan; 18(1):102-7. PubMed ID: 21707870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired coagulation-factor deficiencies.
    Hocking DR
    Med J Aust; 1970 Mar; 1(13):657-9. PubMed ID: 5427311
    [No Abstract]   [Full Text] [Related]  

  • 28. Naturally occurring anticoagulants: a case report.
    Ross SA
    N Z Med J; 1968 Mar; 67(430):411-3. PubMed ID: 4968117
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
    Knöbl P; Derfler K
    Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Circulating anticoagulants. Clinical conditions of diagnosis].
    Godeau P; Blétry O; Piette JC; Wechsler B
    Rev Med Interne; 1985 Dec; 6(5):523-41. PubMed ID: 3938557
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

  • 35. Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors.
    Ruinemans-Koerts J; Peterse-Stienissen I; Verbruggen B
    Thromb Haemost; 2010 Nov; 104(5):1080-2. PubMed ID: 20806127
    [No Abstract]   [Full Text] [Related]  

  • 36. Macrohematuria as initial presentation in a girl with factor VIII and factor IX inhibitors associated with systemic lupus erythematosus.
    Shen CY; Fu LS; Lin HK; Han SM; Wang JD
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):e344-5. PubMed ID: 23018565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
    Millner AH; Tiefenbacher S; Robinson M; Boesen HT
    Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired factor-IX inhibitor in a nonhaemophilic patient with autoimmune disease.
    Largo R; Sigg P; von Felten A; Straub PW
    Br J Haematol; 1974 Jan; 26(1):129-40. PubMed ID: 4211775
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.